Verve Crashes After FDA Halts Plan To Test Gene Editor In People

 U.S. officials halted Verve Therapeutics' (VERV) plan to begin testing in people a gene-editing approach to high cholesterol on Monday, leading VERV stock to crash.

Verve had asked the Food and Drug Administration for permission to test its treatment in 40 patients with high cholesterol due to a genetic defect. The company hopes to use a next-generation form of CRISPR gene editing to permanently turn off a problematic gene in these patients.

Instead, the FDA placed Verve's application on hold. Verve, which has already begun human tests in New Zealand and the U.K., says it will likely receive the FDA's questions within a month.

In premarket trades on today's stock market, VERV stock collapsed 24.9% near 23.50.

https://www.investors.com/news/technology/verv-stock-crashes-after-fda-halts-plans-to-begin-testing-gene-editor-in-people/